AUPH Q3 2025 Earnings — Aurinia Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

AUPHAurinia Pharmaceuticals Inc.

$2B

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$73M+8.4% YoY

Gross Profit

$65M88.4% margin

Operating Income

$30M40.5% margin

Net Income

$32M42.9% margin

EPS (Diluted)

$0.23

QoQ Revenue Growth

+4.9%

Cash Flow

Operating Cash Flow

$44M

Free Cash Flow

$44M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$528M

Total Liabilities

$162M

Stockholders' Equity

$366M

Cash & Equivalents

$73M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$73M	$68M	+8.4%
Gross Profit	$65M	$62M	+5.2%
Operating Income	$30M	$12M	+153.2%
Net Income	$32M	$14M	+119.9%

Revenue Segments

Product

$71M96%

License, Collaboration and Royalty Revenue

$3M4%